President and Chief Executive Officer, Coley Pharmaceutical Group
Dr. Bratzler has been our President, Chief Executive Officer and a director since June 1998. A co-founder of Sepracor Inc., a research-based pharmaceutical company, in 1984, Dr. Bratzler also co-founded and helped build and finance several Sepracor group companies, including ChiRex Inc., a pharmaceutical outsourcing company, where Dr. Bratzler served as President and Chief Executive Officer from 1996 to 1997. A former faculty member in the department of chemical engineering at Princeton University, Dr. Bratzler received his B.S. degree from the University of Michigan and his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

President and Chief Executive Officer
Mr. Bate is President and Chief Executive Officer of NitroMed, Inc. Mr. Bate most recently served as executive vice president at Millennium Pharmaceuticals where, through 2004, his duties included chief financial officer and head of commercial operations. In 1999, he co-founded JSB Partners, an investment banking and transaction advisory firm focused on the biopharmaceutical industry. He was a partner at JSB Partners until 2002. From 1997 to 1999, Mr. Bate served as senior managing director and chief executive officer of MPM Capital, LP, a venture capital company. He was also an advisor to BB Bioventures, a venture capital fund. Mr. Bate's life sciences industry experience also includes six years at Biogen (now Biogen IDEC); from 1993 to 1996 as the company's vice president of sales and marketing, and as chief financial officer from 1990 to 1993. Currently a director of Cubist Pharmaceuticals, Inc. and Coley Pharmaceutical Group, Inc., he is a graduate of Williams College and The Wharton School of the University of Pennsylvania, where he earned an M.B.A.

Managing General Partner, Venrock Associates
Dr. Evnin has served as a director since August 2003. Dr. Evnin has been a Managing General Partner of Venrock Associates, a venture capital firm, since 1980. Dr. Evnin presently serves on the boards of directors of Memory Pharmaceuticals Corp., Icagen, Inc., Renovis, Inc. and several private companies. He led Venrock's investment in Athena Neurosciences, Centocor, Genetics Institute, IDEC Pharmaceuticals, IDEXX Laboratories and Sepracor. Dr. Evnin received his A.B. degree from Princeton University and received his Ph.D. in chemistry from the Massachusetts Institute of Technology.

President and Chief Operating Officer, Celgene Corporation
Robert J. Hugin has been President and Chief Operating Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease since May 2006, and has been a Director of Celgene since December 2001. Mr. Hugin served as Chief Financial Officer of Celgene from 1999 to 2006. Mr. Hugin also serves as a Director of The Medicines Company and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an A.B. degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps. infantry officer during the intervening period.

Formerly President, Research and Development, Rhône Poulenc Rorer
Dr. Karobath has served as a director since December 1999. Dr. Karobath served as President of research and development and Executive Vice President of Rhône-Poulenc Rorer (now sanofi-aventis), a pharmaceutical company, from 1992 to 1999. Prior to that, Dr. Karobath served as Senior Vice President and Head of Research and Development, Switzerland for Sandoz Pharmaceuticals (now Novartis) in Basel, Switzerland. Dr. Karobath currently serves as a director on the boards of Qiagen N.V. and a number of privately held companies. He became a professor of biological psychiatry in 1979 at the University of Vienna Medical School.

General Partner
PJL Conseils
Formerly Executive Vice President and Chief Financial Officer, Aventis S.A
Patrick J. Langlois, Ph.D. is General Partner of PJL Conseils, a consulting firm, since March 2005. He served as Vice Chairman of Aventis' Management Board and Chief Financial Officer from May 2002 to September 2004 and as Executive Vice President and Chief Financial Officer of Aventis S.A. from December 1999 to May 2002. At Aventis, Mr. Langlois was responsible for finance and corporate development functions as well as three global businesses: chemicals, protein therapeutics and animal health. Prior to joining Aventis, Mr. Langlois was employed by the Rhône-Poulenc Group from 1975 to 1999, most recently as Chief Financial Officer and Member of the Executive Committee. Mr. Langlois received a License degree from the University of Rennes in 1967 and a Ph.D. degree from the University of Rennes in 1968 and was awarded a Diploma in Higher Banking Studies in 1974.

Partner, Thomas, McNerney & Partners
Mr. Thomas has served as a director since September 2003. He has been a partner of Thomas, McNerney & Partners, L.L.C., a venture capital firm based in Stamford, Connecticut since 2001. Prior to co-founding Thomas, McNerney & Partners, Mr. Thomas was employed by E.M. Warburg, Pincus & Co., L.L.C.'s health care technology private equity practice from 1989 to 2000, most recently as a managing director. Mr. Thomas is currently a board member of a number of privately held companies. Mr. Thomas received his B.A. degree from the Wharton School of the University of Pennsylvania and also holds an advanced degree in economics from the London School of Economics.